Brief: Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
14/05/2024 13:46
May 14 (Reuters) - Equillium Inc EQ.O :
* EQUILLIUM ANNOUNCES INTERIM ENROLLMENT ACHIEVED IN PHASE 3
EQUATOR STUDY OF ITOLIZUMAB IN ACUTE GRAFT-VERSUS-HOST DISEASE
* EQUILLIUM INC - DELIVERY OF INTERIM DATA REVIEW TO ONO
PHARMACEUTICAL CO. LTD. (ONO) EXPECTED DURING Q3 WILL TRIGGER
ONO'S OPTION EXERCISE PERIOD
Source text for Eikon: ID:nBw1VRvK3a
Further company coverage: EQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations